[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.17.16. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,028
Citations 0
Comment & Response
September 8, 2015

Ramelteon for Delirium in Hospitalized Patients

Author Affiliations
  • 1Department of Psychiatry, Juntendo University Nerima Hospital, Tokyo, Japan
  • 2Department of Psychiatry, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan
  • 3Department of Psychiatry, Hiroshima City Hospital, Hiroshima, Japan
JAMA. 2015;314(10):1071-1072. doi:10.1001/jama.2015.8522

To the Editor In a From The JAMA Network article, Drs Perkisas and Vandewoude1 recommended caution in interpretation of our findings in the randomized placebo-controlled trial of ramelteon for prevention of delirium.2 The points that concerned them were (1) a nonsignificant baseline imbalance in the frequency of dementia in the placebo group and the ramelteon group and (2) that we did not clearly indicate to which treatment group 24 patients admitted to intensive care units were allocated. To clarify these points, we performed subanalyses of the original data.

First Page Preview View Large
First page PDF preview
First page PDF preview
×